This study is for older adults or those not fit for stronger treatments with a type of blood cancer called acute myeloid leukemia (AML) that has a specific change in the FLT3 gene. It compares two treatments: the usual treatment with azacitidine and venetoclax, and a new combination adding gilteritinib. Azacitidine helps activate genes that stop cancer growth. Venetoclax blocks a protein that cancer cells need to survive. Gilteritinib stops cancer cells from multiplying. The study aims to see if the new combination is better at helping patients achieve remission, which means the cancer is less active or gone for a time.

• The study lasts up to 2 years with regular cycles of treatment.
• Participants need regular visits for treatment and tests, including blood samples and bone marrow checks.
• Potential side effects and safety of the treatments will be monitored closely.